Holistyczne podejście do leczenia metotreksatem w reumatologii i dermatologii Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2022
Słowa kluczowe:
reumatoidalne zapalenie stawów, łuszczyca, łuszczycowe zapalenie stawów, metotreksat, forma doustna, forma podskórna
##plugins.themes.bootstrap3.article.main##
Abstrakt
Metotreksat w formie doustnej lub podskórnej jest zarejestrowany m.in. w leczeniu reumatoidalnego zapalenia stawów, łuszczycy i łuszczycowego zapalenia stawów. Wybór formy powinien opierać się na analizie potrzeb i stanu danego pacjenta oraz właściwości farmakologicznych danej formy. W pracy przedstawiono różnice między formą doustną a formą podskórną metotreksatu.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Kwiatkowska, B. (2022). Holistyczne podejście do leczenia metotreksatem w reumatologii i dermatologii . Medycyna Faktów , 15(3(56), 293-296. https://doi.org/10.24292/01.MF.0322.3
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Cronstein BN, Thomas MA. Methotrexate and its mechanisms of action in inflammatory arthritis. Nature Review Rheumatology. 2020; 16: 145-54.
2. Coates LC, Helliwell PS. Methotrexate efficacy in the tight control in psoriatic arthritis study. J Rheumatol. 2016; 43: 356-61.
3. Smolen JS, Landewé R BM, Bijlsma WJ et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79: 685-99.
4. Coates LC, Helliwell S. Methotrexate efficacy in the Tight Control in Psoriatic arthritis (TICOPA) study. J Rheumatol. 2016; 43(2): 356-61.
5. Merola JF, Ogdie A. SEAM-PsA: Seems like methotrexate works in Psoriatic Arthritis? Arthritis Rheumatol. 2019; 71(7): 1027-9.
6. Coates LC, Soriano E, Corp N et al. The Group For Research And Assessment Of Psoriasis And Psoriatic Arthritis (GRAPPA) treatment recommendations 2021. Ann Rheum Dis. 2021; 10.1136/annrheumdis-2021-eular.4091.
7. Smolen JS, Landewé RBM, Bijlsma JWJ et al. EULAR recommendations for the managememnt of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79: 685-99.
8. Generali E, Carrara G, Bortoluzzi A et al. Non-adherence and discontinuation rate for oral and parenteral methotrexate: A retrospective-cohort study in 8,952 patients with psoriatic arthritis. J Transl Autoimmun. 2021; 4: 100113.
9. Christien KHL, Baker K, Jones T et al. Safety and Tolerability of Subcutaneous Methotrexate in Routine Clinical Practice. Arthritis Care Res. 2020. http://doi.org/10.1002/acr.24334.
10. Herman RA, Veng-Pedersen P, Hoffman J et al. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci. 1989; 78(2): 165-71.
11. Murakami T, Mori N. Involvement of multiple transporters-mediated transports in mozoribine and methotrexate pharmacokinetics. Pharmaceuticals (Basel). 2012; 5: 812.
12. Bello AE, Perkins EL, Jay R et al. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatology. Research and Reviews 2017; 9: 67-79 za Pichlmeier U, Heuer KU. Clin Exp Rheumatol. 2014; 32(4): 563-71.
13. O’Connor A, Thorne C, Kang H et al. The rapid kinetics of optimal treatment with subcutaneus methotrexate in early inflammatory arthritis: an observational study. BMC. Musculoskeletal Disord. 2016; 17(1): 364.
14. Bujor AM, Janjua S, LaValley MP et al. Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: A meta-analysis. PLOSE ONE. 2019; 14(9): e0221823.
15. Braun J, Kästner P, Flaxenberg P et al. Comparison of the Clinical Efficacy and Safety of Subcutaneous Versus Oral Administration of Methotrexate in Patients With Active Rheumatoid Arthritis. Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008; 58: 73-81.
16. Christen KH Li, Baker K, Jones T et al. Safety and Tolerability of Subcutaneous Methotrexate in Routine Clinical Practice. Arthritis Care Res. 2021; 73(9): 1306-11.
17. Kromann CB, Lage-Hansen PR, Koefoed M et al. Does switching from oral to subcutaneous administration of methotrexate influence on patient reported gastro-intestinal adverse effects? J Dermatol Treat. 2015; 26(2): 188-90. http://doi.org/10.3109/09546634.2014.927817.
18. Dervieux T, Zablocki R, Kremer J. Red Blood Cell Methotrexate Polyglutamates Emerge as a Function of Dosage Intensity and Route of Administration During Pulse Metho trexate Therapy in Rheumatoid Arthritis. Rheumatology 2010; 49: 2337-45.
19. Senbel E, Tropé S, Herman-Demars H et al. Benefits of Switch from Oral to Subcutaneous Route on Adherence to Methotrexate in Patients with Rheumatoid Arthritis in Real Life Setting. Patient Prefer Adherence. 2021; 15: 751-60.
2. Coates LC, Helliwell PS. Methotrexate efficacy in the tight control in psoriatic arthritis study. J Rheumatol. 2016; 43: 356-61.
3. Smolen JS, Landewé R BM, Bijlsma WJ et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79: 685-99.
4. Coates LC, Helliwell S. Methotrexate efficacy in the Tight Control in Psoriatic arthritis (TICOPA) study. J Rheumatol. 2016; 43(2): 356-61.
5. Merola JF, Ogdie A. SEAM-PsA: Seems like methotrexate works in Psoriatic Arthritis? Arthritis Rheumatol. 2019; 71(7): 1027-9.
6. Coates LC, Soriano E, Corp N et al. The Group For Research And Assessment Of Psoriasis And Psoriatic Arthritis (GRAPPA) treatment recommendations 2021. Ann Rheum Dis. 2021; 10.1136/annrheumdis-2021-eular.4091.
7. Smolen JS, Landewé RBM, Bijlsma JWJ et al. EULAR recommendations for the managememnt of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79: 685-99.
8. Generali E, Carrara G, Bortoluzzi A et al. Non-adherence and discontinuation rate for oral and parenteral methotrexate: A retrospective-cohort study in 8,952 patients with psoriatic arthritis. J Transl Autoimmun. 2021; 4: 100113.
9. Christien KHL, Baker K, Jones T et al. Safety and Tolerability of Subcutaneous Methotrexate in Routine Clinical Practice. Arthritis Care Res. 2020. http://doi.org/10.1002/acr.24334.
10. Herman RA, Veng-Pedersen P, Hoffman J et al. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci. 1989; 78(2): 165-71.
11. Murakami T, Mori N. Involvement of multiple transporters-mediated transports in mozoribine and methotrexate pharmacokinetics. Pharmaceuticals (Basel). 2012; 5: 812.
12. Bello AE, Perkins EL, Jay R et al. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatology. Research and Reviews 2017; 9: 67-79 za Pichlmeier U, Heuer KU. Clin Exp Rheumatol. 2014; 32(4): 563-71.
13. O’Connor A, Thorne C, Kang H et al. The rapid kinetics of optimal treatment with subcutaneus methotrexate in early inflammatory arthritis: an observational study. BMC. Musculoskeletal Disord. 2016; 17(1): 364.
14. Bujor AM, Janjua S, LaValley MP et al. Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: A meta-analysis. PLOSE ONE. 2019; 14(9): e0221823.
15. Braun J, Kästner P, Flaxenberg P et al. Comparison of the Clinical Efficacy and Safety of Subcutaneous Versus Oral Administration of Methotrexate in Patients With Active Rheumatoid Arthritis. Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008; 58: 73-81.
16. Christen KH Li, Baker K, Jones T et al. Safety and Tolerability of Subcutaneous Methotrexate in Routine Clinical Practice. Arthritis Care Res. 2021; 73(9): 1306-11.
17. Kromann CB, Lage-Hansen PR, Koefoed M et al. Does switching from oral to subcutaneous administration of methotrexate influence on patient reported gastro-intestinal adverse effects? J Dermatol Treat. 2015; 26(2): 188-90. http://doi.org/10.3109/09546634.2014.927817.
18. Dervieux T, Zablocki R, Kremer J. Red Blood Cell Methotrexate Polyglutamates Emerge as a Function of Dosage Intensity and Route of Administration During Pulse Metho trexate Therapy in Rheumatoid Arthritis. Rheumatology 2010; 49: 2337-45.
19. Senbel E, Tropé S, Herman-Demars H et al. Benefits of Switch from Oral to Subcutaneous Route on Adherence to Methotrexate in Patients with Rheumatoid Arthritis in Real Life Setting. Patient Prefer Adherence. 2021; 15: 751-60.